Search - tctmd.com

Displaying 421 - 440 of 1120

Sort: Relevancy | Date

Presentation TCT 2016

Management Options for Postsurgical Paravalvular Aortic Regurgitation

Presenter: Alejandro Cherro, Fernando Cura

October 30, 2016

Presentation TCT 2016

Low-Risk Studies: Design and Updates I - The UK All-Comer TAVI Study

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Neil E. Moat

October 30, 2016

Presentation TCT 2016

TCT 825: Simplicity Denervation System for Pulmonary Artery Denervation in Patients with Chronic Thrombembolic Pulmonary Hypertension (first-in-man study)

Presenter: Irene M. Lang, Ehtisham Mahmud

October 30, 2016

Presentation TCT 2016

Prognostic and Treatment Decision Implications of Exercise Induced Mitral Regurgitation

Presenter: Paul A. Grayburn, Patrizio Lancellotti

October 30, 2016

Presentation TCT 2016

Argentina Presents a Case of a Percutaneous Closure of Paravalvular Aortic Regurgitation

Presenter: Alejandro Cherro, Raul Solerno

October 30, 2016

Presentation TCT 2016

The TAVR Development Journey: Lessons Learned and Drivers of Success

Presenter: John G. Webb, Ajit Yoganathan

October 30, 2016

Presentation TCT 2016

Echo Quantification of MR Severity: Classification and Common Pitfalls

Presenter: Paul A. Grayburn, Patrizio Lancellotti

October 30, 2016

Presentation TCT 2016

Intermediate-Risk Studies II: Updates From SURTAVI

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Jeffrey J. Popma

October 30, 2016

Presentation TCT 2016

Risk Scores for Stroke Risk and Bleeding in Atrial Fibrillation: Accuracy and Utility in Trials and the Real World

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt, Christopher B. Granger

October 30, 2016

Presentation TCT 2016

Brazil Presents a Case: Complex Access in TAVI the Transcaval Approach

Presenter: Rui Campante Teles, Marcelo Jose de Carvalho Cantarelli, Dimytri Alexandre Siqueira

October 30, 2016

Presentation TCT 2016

Intermediate-Risk Studies I: Synthesis of the PARTNER 2A and the Sapien 3 Intermediate-Risk Trials

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Susheel K. Kodali

October 30, 2016

Presentation TCT 2016

Outcomes and Role of Ablation in the Treatment Approach to Atrial Fibrillation

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt, Vivek Y. Reddy

October 30, 2016

Presentation TCT 2016

Real-world Requirements and Expectations for TAVR in Lower Risk Patients

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Martin B. Leon

October 30, 2016

Presentation TCT 2016

What are Valid Absolute and Relative Contraindications to Warfarin and NOACs?

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt

October 30, 2016

Presentation TCT 2016

Transcatheter Mitral Replacement Devices: An Update from the International Organization for Standardization (ISO) Cardiac Valves Committee

Presenter: Elazer R. Edelman, Juan F. Granada, Changfu Wu, Aaron Chalekian

October 30, 2016

Presentation TCT 2016

Whats New and What's Controversial in the US and EU Guidelines?

Presenter: Ted Feldman, Allan Schwartz, Catherine M. Otto

October 30, 2016

Presentation TCT 2016

Flash Debate: Counterpoint - Guidelines Have Limited Value in Rapidly Evolving Transcatheter Valve Therapies!

Presenter: Patrick T. O'Gara, Alec S. Vahanian, John G. Webb

October 30, 2016

Presentation TCT 2016

Warfarin and NOACS for Atrial Fibrillation: Efficacy, Complications, and Compliance

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt, Michelle O'Donoghue

October 30, 2016

Presentation TCT 2016

Medical Therapy, Revascularization, and CRT for Functional Mitral Regurgitation: Despite Class I Guidelines, Are the Benefits Substantial?

Presenter: Ted Feldman, Allan Schwartz, JoAnn Lindenfeld

October 30, 2016

Presentation TCT 2016

Animal Testing: Real-World Experiences and Translational Challenges

Presenter: Elazer R. Edelman, Juan F. Granada, Changfu Wu

October 30, 2016

Advertisement

Management Options for Postsurgical Paravalvular Aortic Regurgitation

Low-Risk Studies: Design and Updates I - The UK All-Comer TAVI Study

TCT 825: Simplicity Denervation System for Pulmonary Artery Denervation in Patients with Chronic Thrombembolic Pulmonary Hypertension (first-in-man study)

Prognostic and Treatment Decision Implications of Exercise Induced Mitral Regurgitation

Argentina Presents a Case of a Percutaneous Closure of Paravalvular Aortic Regurgitation

The TAVR Development Journey: Lessons Learned and Drivers of Success

Echo Quantification of MR Severity: Classification and Common Pitfalls

Intermediate-Risk Studies II: Updates From SURTAVI

Risk Scores for Stroke Risk and Bleeding in Atrial Fibrillation: Accuracy and Utility in Trials and the Real World

Brazil Presents a Case: Complex Access in TAVI the Transcaval Approach

Intermediate-Risk Studies I: Synthesis of the PARTNER 2A and the Sapien 3 Intermediate-Risk Trials

Outcomes and Role of Ablation in the Treatment Approach to Atrial Fibrillation

Real-world Requirements and Expectations for TAVR in Lower Risk Patients

What are Valid Absolute and Relative Contraindications to Warfarin and NOACs?

Transcatheter Mitral Replacement Devices: An Update from the International Organization for Standardization (ISO) Cardiac Valves Committee

Whats New and What's Controversial in the US and EU Guidelines?

Flash Debate: Counterpoint - Guidelines Have Limited Value in Rapidly Evolving Transcatheter Valve Therapies!

Warfarin and NOACS for Atrial Fibrillation: Efficacy, Complications, and Compliance

Medical Therapy, Revascularization, and CRT for Functional Mitral Regurgitation: Despite Class I Guidelines, Are the Benefits Substantial?

Animal Testing: Real-World Experiences and Translational Challenges

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content